Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03573336 · ClinicalTrials.gov registry record · Phase 2
Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03573336 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 8 participants.
The verdict
NCT03573336, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of this study was to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis. The secondary objective of this study was to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis. With the implementation of protocol version 4.0 dated 11-Dec-2018, no new subjects were enrolled. The objectives above cannot be reached as only limited data is available from subjects recruited before the temporary pause.
Interventions
- DRUG Matching Placebo
- DRUG Vilaprisan (BAY1002670)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-07-04 |
| Est. Completion | 2020-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03573336
The ClinicalTrials.gov registry entry for NCT03573336 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT03573336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03573336 about?
NCT03573336 is a clinical study titled "Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis". The primary objective of this study was to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis. The secondary objective of this study was to evaluate the safety and tolerability of two different doses of vilaprisan in women with symp...
What is the current status of trial NCT03573336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2018-07-04. Estimated completion is 2020-11-26.
What interventions are being tested in trial NCT03573336?
The interventions under investigation include: Matching Placebo (DRUG), Vilaprisan (BAY1002670) (DRUG).
Who is sponsoring clinical trial NCT03573336?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.